<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04834986</url>
  </required_header>
  <id_info>
    <org_study_id>GDS20201110564038</org_study_id>
    <nct_id>NCT04834986</nct_id>
  </id_info>
  <brief_title>Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma</brief_title>
  <official_title>A Prospective, One-arm, Phase II Clinical Study of Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma With a High Risk of Recurrence.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tianjin Medical University Cancer Institute and Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with&#xD;
      Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a&#xD;
      high risk of recurrence.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety as measured by the number of grade 3 and grade 4 adverse events that occurred when subjects participated in the study, as defined by CTCAE v5.0.</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility as measured by rate of enrollment</measure>
    <time_frame>3 months</time_frame>
    <description>It's defined as a delay of surgery for any reason no more than 49 days compared to the specified planned surgery time (i.e., delay of surgery ≤42 days and scheduled surgery for 7 days).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>objective response rate(ORR)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year disease-free survival rate (1-year DFS%)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pathological complete response(pCR)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-year disease-free survival rate (2-year DFS%)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease-free survival(DFS)</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse reactions</measure>
    <time_frame>36 months</time_frame>
    <description>AEs and SAE</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To explore genomic biomarkers of clinical remission/drug resistance (TMB, TNB, ITH, HLA subtype, HLA-LOH ) in combination with Tislelizumab and Lenvatinib.</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Identification of tumor microenvironmental biomarkers (tumor Infiltrating lymphocytes, biomarkers expressed on T cells ) for clinical remission/drug resistance in combination with Tislelizumab and Lenvatinib.</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>To investigate the clinical efficacy of PD-L1 expression in predicting the combination of Tislelizumab and Lenvatinib.</measure>
    <time_frame>36 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Resectable Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Tislelizumab combined with Lenvatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tislelizumab combined with Lenvatinib</intervention_name>
    <description>Pre-operation: Tislelizumab, 200mg, iv,d1,q3w, 2-4 cycles; Lenvatinib,8mg/kg,po,qd,d1-d84.&#xD;
Operation Postoperation: 4-8 weeks after surgery, Tislelizumab, 200mg, iv,d1,q3w; Lenvatinib,8mg/kg,po,qd, up to one year.</description>
    <arm_group_label>Tislelizumab combined with Lenvatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients volunteered to participate in this study and signed informed consent;&#xD;
&#xD;
          -  Age 18-75, male or female;&#xD;
&#xD;
          -  ECOG PS score 0-1;&#xD;
&#xD;
          -  Child-pugh liver function grading: Grade A&#xD;
&#xD;
          -  The clinical diagnosis conforms to primary hepatocellular carcinoma (HCC) and the&#xD;
             lesion conforms to the indications for resectable operation in the Guidelines for&#xD;
             diagnosis and Treatment of HCC (2019) edition;&#xD;
&#xD;
          -  According to the preoperative evaluation of the researcher, the patient had a high&#xD;
             risk of recurrence and met at least one of the risk factors:&#xD;
&#xD;
             Ⅰb: a single tumor diameter &gt; 6.5 cm (except Mr Tian Bangxiong inflating),2-3 tumors&#xD;
             with the maximum diameter ≤3cm;&#xD;
&#xD;
               -  a : tumor 2-3,biggest &gt; 3 cm in diameter&#xD;
&#xD;
               -  b: tumor 4 or higher&#xD;
&#xD;
                    -  a: vascular invasion to the naked eyes;&#xD;
&#xD;
          -  According to RECIST 1.1 standard, patients have at least one measurable lesion (CT/MRI&#xD;
             scan long diameter ≥10mm or CT/MRI scan short diameter ≥15mm for lymph node lesions,&#xD;
             and the lesion has not received radiotherapy, freezing or other local treatments);&#xD;
&#xD;
          -  Expected survival ≥ 6 months;&#xD;
&#xD;
          -  The function of vital organs meets the following requirements (excluding the use of&#xD;
             any blood component and cell growth factor within 14 days) ;&#xD;
&#xD;
        Blood routine:&#xD;
&#xD;
        Neutrophils ≥1.5×109//L Platelet count ≥100×109/L Hemoglobin ≥90g/L;&#xD;
&#xD;
        Liver and kidney function:&#xD;
&#xD;
        Serum creatinine (SCr) ≤ 1.5 times upper limit of normal value (ULN) or creatinine&#xD;
        clearance ≥50 ml/min (Cockcroft-Gault formula); Total bilirubin (TBIL)≤ 1.5 times the upper&#xD;
        limit of normal value (ULN); AST or ALT levels ≤ 2.5 times the upper limit of normal value&#xD;
        (ULN); Urine protein &lt;2+;If urinary protein ≥2+,24-hour quantitative urine protein must be&#xD;
        ≤1g;&#xD;
&#xD;
          -  Normal coagulation function, no active bleeding and thrombotic disease A.&#xD;
             International standardized ratio INR≤1.5×ULN; B. Partial thromboplastin time&#xD;
             APTT≤1.5×ULN; C. Prothrombin time PT≤1.5ULN;&#xD;
&#xD;
          -  Women of childbearing age should agree to use contraceptives (such as intrauterine&#xD;
             devices, contraceptives or condoms) during and within six months of the end of&#xD;
             medication; Patients with negative serum or urine pregnancy tests within 7 days prior&#xD;
             to study inclusion and who must be non-lactating, and males should agree to use&#xD;
             contraceptives during the study period and for 6 months after the end of the study&#xD;
             period;&#xD;
&#xD;
          -  Subjects have good compliance and cooperate with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have received radiotherapy, chemotherapy, concurrent chemoradiotherapy or other&#xD;
             targeted therapies before;&#xD;
&#xD;
          -  Known hepatobiliary cell carcinoma, sarcomatoid hepatocellular carcinoma, mixed cell&#xD;
             carcinoma and fibre-lamellar cell carcinoma; Active malignancies other than HCC within&#xD;
             5 years or concurrently;&#xD;
&#xD;
          -  Having hypertension that cannot be well controlled by antihypertensive drug therapy&#xD;
             (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);Previous&#xD;
             history of hypertension crisis or hypertensive encephalopathy;&#xD;
&#xD;
          -  Subject has previous or concurrent malignancies (except cured basal cell carcinoma of&#xD;
             skin and carcinoma in situ of the cervix);&#xD;
&#xD;
          -  Previous treatment with Tislelizumab or other PD-1/PD-L1 treatment could not be&#xD;
             enrolled; Subjects are known to have prior allergies to macromolecular protein&#xD;
             reparations or to any Tislelizumab or Lenvatinib excipients;&#xD;
&#xD;
          -  Subject has any active autoimmune disease or history of autoimmune disease (such as,&#xD;
             but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis,&#xD;
             hepatitis, pituitary inflammation, vasculitis, nephritis, hyperthyroidism,&#xD;
             hypothyroidism; Subjects with vitiligo or childhood asthma have been completely&#xD;
             relieved and may be included as adults without any intervention; Asthma requiring&#xD;
             medical intervention with bronchodilators will not be included);&#xD;
&#xD;
          -  Subjects are receiving immunosuppressive, or systemic, or absorbable local hormone&#xD;
             therapy for immunosuppression purposes (&gt;10mg/ day prednisone or other therapeutic&#xD;
             hormones) and continue to receive such therapy within 2 weeks prior to enrollment;&#xD;
&#xD;
          -  Ascites or pleural effusion with clinical symptoms require therapeutic puncture or&#xD;
             drainage;&#xD;
&#xD;
          -  Clinical symptoms or diseases of the heart that are not well controlled, such as:&#xD;
&#xD;
               1. NYHA2 or above heart failure&#xD;
&#xD;
               2. Unstable angina pectoris&#xD;
&#xD;
               3. Myocardial infarction occurred within 1 year&#xD;
&#xD;
               4. Patients with clinically significant supraventricular or ventricular arrhythmia&#xD;
                  requiring treatment or intervention;&#xD;
&#xD;
          -  The patient currently (within 3 months) has gastrointestinal diseases such as&#xD;
             esophageal varices, active gastric and duodenal ulcers, ulcerative colitis, portal&#xD;
             hypertension, or active bleeding in unresected tumors, or other conditions determined&#xD;
             by the researchers that may cause gastrointestinal bleeding or perforation;&#xD;
&#xD;
          -  Past or present severe bleeding (&gt;30 ml bleeding within 3 months), hemoptysis (&gt;5 ml&#xD;
             fresh blood within 4 weeks) or thromboembolic events (including stroke events and/or&#xD;
             tia) within 12 months;&#xD;
&#xD;
          -  Subject has active infection or unexplained fever of &gt;38.5 degrees during screening&#xD;
             and before first administration (subject's fever due to tumor can be enrolled&#xD;
             according to the investigator's judgment);&#xD;
&#xD;
          -  Patients with past or present objective evidence of pulmonary fibrosis, interstitial&#xD;
             pneumonia, pneumoconiosis, radioactive pneumonia, drug related pneumonia, severe&#xD;
             impairment of lung function, etc.;&#xD;
&#xD;
          -  Subjects with congenital or acquired immune deficiency, such as HIV infection, or&#xD;
             active hepatitis (transaminase does not meet the inclusion criteria, hepatitis B&#xD;
             reference: HBV DNA≥1000/ml; Hepatitis C reference: HCV RNA≥103/ml);Chronic hepatitis B&#xD;
             virus carriers, HBV DNA &lt; 1000 IU/ml, must receive antiviral treatment at the same&#xD;
             time during the test can be enrolled;&#xD;
&#xD;
          -  Live vaccine is administered less than 4 weeks before or possibly during the study&#xD;
             period;&#xD;
&#xD;
          -  The subject has a known history of psychotropic substance abuse, alcohol abuse or drug&#xD;
             abuse;&#xD;
&#xD;
          -  The subject cannot or does not agree to bear the cost of the self-funded portion of&#xD;
             the examination and treatment, except for the clinical study drug, combined&#xD;
             chemotherapy and SAE related to the clinical study drug combined chemotherapy;&#xD;
&#xD;
          -  Researchers think that should be left out in this study, the researchers determine,&#xD;
             for example, the subjects have other factors that may result in this study were forced&#xD;
             to midway termination, such as, other serious disease (including mental illness) need&#xD;
             to merge treatment, there are serious abnormal laboratory examination, accompanied by&#xD;
             factors such as family or society, will affect the safety of the subjects, or&#xD;
             information and the collection of the sample.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tianjin Medical University Cancer Insititute and Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 6, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 8, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenvatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

